# Alder BioPharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alder-biopharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Bothell, US
- Website: www.alderbio.com
- Total disclosed funding: $105M
- Latest round: Series D (Apr 19, 2012)
- Investors on record: 7

## About

Alder BioPharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of pain and migraine, utilizing advanced biological techniques to enhance patient care.Founded in 2004 in Bothell, US, Alder BioPharmaceuticals develops and commercializes therapeutic solutions targeting chronic pain and migraines. The company successfully raised USD 82.8 mn through an IPO on May 8, 2014, marking a significant milestone in its funding history. The company has executed a total of 7 deals since inception. The firm's founder has a history in the biopharmaceutical industry, although specific previous ventures are not detailed.Alder BioPharmaceuticals specializes in the development of monoclonal antibody therapies, focusing on migraine prevention and pain management. Their lead product candidates are designed to target the mechanisms of migraine and aim to improve the quality of life for patients suffering from chronic headaches. The therapies are under clinical development and cater to a diverse patient population across various demographics, aiming to address the unmet needs in migraine treatment.In the most recent year, Alder BioPharmaceuticals reported zero revenue, with an EBITDA of USD -284.02 mn for the year 2018, indicating significant investment in research and development as the company continues to advance its product pipeline.Alder BioPharmaceuticals plans to utilize the funds raised from its IPO to accelerate the development of its drug candidates and expand clinical trials. The company is focusing on launching its new therapies within the next few years, specifically targeting the migraine market in North America and Europe. The recent IPO has positioned Alder BioPharmaceuticals to enhance its R&D capabilities and potentially expand into other international markets as part of its long-term growth strategy.

## Funding rounds

- Series D, Apr 19, 2012, $38M — Delphi Ventures, Sevin Rosen Funds, Ventures West Capital, H.I.G. BioHealth Partners, Novo Holdings, TPG Biotech, WRF Capital
- Series C, Jan 11, 2008, $40M — Delphi Ventures, Sevin Rosen Funds, Ventures West Capital, H.I.G. BioHealth Partners, TPG Biotech, WRF Capital
- Series B, Jul 11, 2006, $16M — Sevin Rosen Funds, Ventures West Capital, H.I.G. BioHealth Partners, WRF Capital
- Series A, Aug 15, 2005, $11M — Sevin Rosen Funds, Ventures West Capital, WRF Capital
- Seed, Jun 1, 2004 — WRF Capital

## Investors

- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Seed, Series A, Series B, Series C, Series D
- Sevin Rosen Funds (https://capitalatlas.ai/funds/sevin-rosen-funds) — Series A, Series B, Series C, Series D
- Ventures West Capital (https://capitalatlas.ai/funds/ventures-west-capital) — Series A, Series B, Series C, Series D
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B, Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series C, Series D
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series C, Series D
- Novo Holdings — Series D